Guidelines
30 June 2025
Vol. 3 No. 2 (2025)
iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Disclaimer
Disclaimer: The Global Implementation Guidelines (the “Documents”) represent the views of its authors. They were produced after careful consideration of the scientific and medical knowledge and the evidence and related economic issues that may impact implementation of therapies, as well as the main guidelines on the topic, available at the time of their publication. The iCARDIO Alliance, respectively its Partner Organizations and the TMA, are not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the Documents and any other official recommendations or guidelines issued by other bodies in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the Documents fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. On the other hand, the Documents do not override the individual responsibility of health professionals to make the appropriate, accurate and individual decisions in consideration of each patient’s health condition. These decisions should be taken in consultation with their individual patient and, where appropriate and/or necessary, the patient’s caregiver. The Documents do not exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines, issued by the competent public health authorities that govern them. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
Disclaimer: The Global Implementation Guidelines (the “Documents”) represent the views of its authors. They were produced after careful consideration of the scientific and medical knowledge and the evidence and related economic issues that may impact implementation of therapies, as well as the main guidelines on the topic, available at the time of their publication. The iCARDIO Alliance, respectively its Partner Organizations and the TMA, are not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the Documents and any other official recommendations or guidelines issued by other bodies in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the Documents fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. On the other hand, the Documents do not override the individual responsibility of health professionals to make the appropriate, accurate and individual decisions in consideration of each patient’s health condition. These decisions should be taken in consultation with their individual patient and, where appropriate and/or necessary, the patient’s caregiver. The Documents do not exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines, issued by the competent public health authorities that govern them. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
13686
Views
9637
Downloads
Authors
Inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices as well as practical and political issues restrict the global applicability of currently available guidelines. There is a need for universal recommendations that address the unique challenges faced by patients and healthcare providers worldwide. Our iCARDIO Alliance Global Implementation Guidelines emphasize the incorporation of novel therapies, while integrating standard of care with the most uptodate evidence to enable clinicians to optimize patient care. This document is about heart failure (HF), including acute and chronic heart failure, heart failure with reduced ejection fraction and heart failure with preserved ejection fraction as well as cardiomyopathies. Context-specific recommendations tailored to individual patient needs are highlighted providing a thorough evaluation of the risks, benefits, and overall value of each therapy, aiming to establish a standard of care that improves patient outcomes and reduces the burden of hospitalization in this susceptible population. These guidelines provide evidence-based recommendations that represent a group consensus considering the many other published guidelines that have reviewed many of the issues discussed here, but they also make new recommendations where new evidence has recently emerged. Most importantly these guidelines also provide recommendations on a number of issues where resource limitations may put constraints on the care provided to HF patients. Such “economic adjustment” recommendations aim to provide guidance for situations when “Resources are somewhat limited” or when “Resources are severely limited”. Hence, this document presents not only a comprehensive but also concise update to HF management guidelines thereby aiming to provide a unified strategy for the pharmacological, nonpharmacological, invasive and interventional management of this significant global health challenge that is applicable to the needs of healthcare around the globe.
Altmetrics
Downloads
Download data is not yet available.
Citations
1. Tromp J, Bamadhaj S, Cleland JGF, et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Glob Health 2020;8:e411-22.
2. Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation 2021;143:e254-e743.
3. Bozkurt B, Ahmad T, Alexander K, et al. HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics An Updated 2024 Report from the Heart Failure Society of America. J Card Fail 2025;31:66-116.
4. No authors listed. Heart failure: management of patients with left-ventricular systolic dysfunction. Clin Pract Guidel Quick Ref Guide Clin. 1994;11:1-21.
5. No authors listed. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995;92:2764-84.
6. Heidenreich PA, Bozkurt B, Aguilar D 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895-1032
7. Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC Expert Consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol.2023;81:1835-78.
8. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-726.
9. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627-39.
10. National Guideline Centre (UK). Chronic Heart Failure in Adults: Diagnosis and Management. London: National Institute for Health and Care Excellence (NICE); 2018.
11. No authors listed. Acute heart failure: diagnosis and management. London: National Institute for Health and Care Excellence (NICE).
12. NHFA CSANZ Heart Failure Guidelines Working Group; Atherton JJ, Sindone A, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the prevention, detection, and management of heart failure in Australia 2018. Heart Lung Circ 2018;27:1123-208.
13. McDonald M, Virani S, Chan M, et al. CCS/CHFS Heart Failure Guidelines Update: Defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol 2021;37:531-46.
14. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017;33:1342-433.
15. Tsutsui H, Isobe M, Ito H, et al. JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version. Circ J 2019;83:2084-184.
16. Tsutsui H, Ide T, Ito H, et al. JCS/JHFS 2021 Guideline focused update on diagnosis and treatment of acute and chronic heart failure. J Card Fail 2021;27:1404-44.
17. Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. [Chinese guidelines for the diagnosis and treatment of heart failure 2018].[Article in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi 2018;46:760-89.
18. Guha S, Harikrishnan S, Ray S, et al. CSI position statement on management of heart failure in India. Indian Heart J 2018;70:S1-72.
19. Huffman MD, Roth GA, Sliwa K, et al. Chapter 10 - Heart failure. In: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Wu Y, Nugent R, editors. Cardiovascular, respiratory, and related disorders. 3rd edition. The International Bank for Reconstruction and Development/The World Bank; 2017.
20. Zubaid M, Rashed W, Ridha M, et al. Implementation of guideline-recommended therapies for patients with heart failure and reduced ejection fraction: A Regional Arab Middle East Experience. Angiology 2020;71:431-7.
21. Zubaid M, Rashed W, Ridha M, et al. Design and Rationale of Gulf Documentation of Ambulatory Sick Patients with Heart Failure (Gulf DYSPNEA) Registry. Heart Views 2018;19:81-4.
22. Al Habeeb W, Tash A, Elasfar A, et al. 2023 National Heart Center/Saudi Heart Association Focused Update of the 2019 Saudi Heart Association Guidelines for the Management of Heart Failure. J Saudi Heart Assoc 2023;35:71-134.
23. Bragazzi NL, Zhong W, Shu J, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol. 2021;28:1682-90.
24. Sulaiman K, Panduranga P, Al-Zakwani I, et al. Clinical characteristics, management, and outcomes of acute heart failure patients: observations from the Gulf acute heart failure registry (Gulf CARE). Eur J Heart Fail 2015;17:374-84.
25. Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med 2012;172:1386-94.
26. Joseph P, Dokainish H, McCready T, et al. A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. Am Heart J 2020;227:56-63.
27. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
28. Anker SD, Friede T, von Bardeleben RS, et al. Transcatheter valve repair in heart failure with moderate to severe mitral regurgitation. N Engl J Med 2024;391:1799-809.
29. von Bardeleben RS, Khan MS, Geyer M, et al. Baseline echocardiographic characteristics of patients enrolled in the randomized investigation of MitraClip device in heart failure (RESHAPE HF-2) trial: comparison with COAPT and Mitra-FR. Global Cardiology 2024;2:40.
30. Anker SD, Butler J, Talha KM, Friede T. Using multiple primary endpoints in clinical trials with a focus on heart failure. Global Cardiology 2024;2:33.
31. Anker MS, Porthun J, Bonnet G, et al. Baseline echocardiographic characteristics of patients enrolled in the randomized investigation percutaneous transcatheter edge-to-edge repair for functional mitral regurgitation in heart failure: a meta-analysis of 3 randomized controlled trials. J Am Coll Cardiol 2024;84:2364-8.
32. Brugts JJ, Radhoe SP, Clephas PRD, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet 2023;401:2113-23.
33. Boehmer JP, Cremer S, Abo-Auda WS, et al. Impact of a novel wearable sensor on heart failure rehospitalization: an open-label concurrent-control clinical trial. JACC Heart Fail 2024;12:2011-22.
34. Kar S, Makkar RR, Whisenant BK, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: the TRILUMINATE PIVOTAL randomized trial. Circulation 2025. Online Ahead of Print.
35. Anker SD, Friede T, Butler J, et al. Intravenous ferric carboxymaltose in heart failure with iron deficiency: the FAIR-HF2 DZHK05 randomized clinical trial. JAMA 2025. Online Ahead of Print.
36. Anker SD, Karakas M, Mentz RJ, et al. Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med 2025. Online Ahead of Print.
37. Talha KM, Butler J, von Haehling S, et al. Defining iron replete status in patients with heart failure treated with intravenous iron. Global Cardiology 2023;1:17.
38. Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024;390:132-42.
39. Judge DP, Alexander KM, Cappelli F, et al. Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 2025;85:1003-14.
40. Fontana M, Berk JL, Gillmore JD, Witteles RM, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med 2025;392:33-44.
41. Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2024;391:1475-85.
42. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069-84.
43. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024;390:1394-407.
44. Butler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet 2024;403:1635-48.
45. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025;392:427-37.
46. Herrmann JJ, Brunner-La Rocca HP, Baltussen LEHJM, et al. Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial. Nat Med 2025. Online Ahead of Print.
47. Pinto FJ, Anker SD, Abraham WT, et al. The Global Implementation Guidelines Initiative: how to optimize cardio-renal-metabolic care worldwide. Global Cardiology 2025;3:68.
How to Cite
1.
Chopra V, Khan MS, Abdelhamid M, Abraham WT, Amir O, Anker SD, et al. iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025. Global Cardiol [Internet]. 2025 Jun. 30 [cited 2026 May 8];3(2). Available from: https://www.globalcardiology.info/site/article/view/70
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
